Iparomlimab Tolvorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma With Microsatellite Instability/Mismatch Repair Deficiency
Clinical trial NCT07595523 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07595523
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-01
- Primary completion
- 2028-07-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.